Supplementary Data — Hydrogen Peroxide reduces COVID-19 risk: real-time meta-analysis of 8 studies

@CovidAnalysis, October 2026, Version 5V5 (V1 2023)
c19early.org
October 2026

Hydrogen peroxide COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mukhtar (RCT)86%0.14 · 0.01–2.69death0/463/46CT1 Mukhtar (RCT)86%0.14 · 0.01–2.69ventilation0/463/46CT1 Mukhtar (RCT)18%0.82 · 0.63–1.07viral+28/4335/44CT1 Mukhtar (RCT)14%0.86 · 0.76–0.98viral+37/4344/44CT1 Jayaraman50%0.50 · 0.23–1.08viral+3/66/6Short term viral Pablo-Marcos12%0.88 · 0.48–1.58viral load17 (n)40 (n) Pablo-Marcos−64%1.64 · 0.83–3.23viral load31 (n)40 (n) Gansky (DB RCT)67%0.33 · 0.02–6.86no recov.0/61/6AMPoL Di Domê.. (DB RCT)50%0.50 · 0.05–5.08ICU1/202/20 Di Domê.. (DB RCT)6%0.94 · 0.37–2.38no improv.18 (n)17 (n) Di Domê.. (DB RCT)7%0.93 · 0.71–1.22no disch.18 (n)17 (n) Di Domê.. (DB RCT)34%0.66 · 0.10–4.55ICU2/772/51 Di Domê.. (DB RCT)−1%1.01 · 0.61–1.67no recov.63 (n)43 (n) Di Domê.. (DB RCT)31%0.69 · 0.24–1.95PASC6/516/35 Agrawal (DB RCT)67%0.33 · 0.04–2.94death1/203/20HOPE in COVID-19 Agrawal (DB RCT)67%0.33 · 0.04–2.94ventilation1/203/20HOPE in COVID-19 Agrawal (DB RCT)46%0.54 · 0.44–0.66oxygen time19 (n)17 (n)HOPE in COVID-19 Agrawal (DB RCT)36%0.64 · 0.55–0.75recov. time19 (n)17 (n)HOPE in COVID-19 Agrawal (DB RCT)39%0.61 · 0.49–0.77recov. time19 (n)17 (n)HOPE in COVID-19 Agrawal (DB RCT)30%0.70 · 0.57–0.87recov. time19 (n)17 (n)HOPE in COVID-19 Agrawal (DB RCT)45%0.55 · 0.45–0.67viral time19 (n)17 (n)HOPE in COVID-19 Amoah93%0.07 · 0.00–1.13cases94 (n)372 (n) Amoah93%0.07 · 0.00–1.25cases0/9410/372 Amoah98%0.02 · 0.00–0.23cases0/862/458
00.511.52+
1 CT: study uses combined treatment
Rotate screen for more detailsIncrease width for more details
← Hydrogen
Peroxide
reduces riskHydrogen
Peroxide
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.